Issue: May 2013
April 22, 2013
1 min read
Save

Enhanced rosehips powder improved osteoarthritis symptoms

Issue: May 2013
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

PHILADELPHIA — An enhanced rose hips powder product improved pain and function in patients with knee osteoarthritis, according to a study presented at the Osteoarthritis Research Society World Congress.

“Rosenoids rose hips powder in 3 capsules is as least as good as the original rosehips powder in 6 capsules a day,” Robin Christensen, MSc, PhD, of The Parker Institute Department of Rheumatology in Copenhagen, said, here.

The researchers designed a rose hips powder product enhanced with fruit husks harvested from Chile. They conducted a randomized controlled trial unfunded by a pharmaceutical company to test their product. In the study, the researchers divided 150 patients with knee osteoarthritis into 3 groups. One group received 6 capsules a day of the original rose hips powder. The second group received 6 capsules of the enhanced rose hips powder and the third group took 3 capsules per day of the enhanced rose hips powder. The primary outcome measure was the Knee Osteoarthritis Outcome Scale (KOOS).

 

Robin Christensen

The researchers found similar scores between all three groups. The one exception was in the KOOS symptoms subscale, where the difference between the groups favored the enhanced rose hips powder with a difference of 5.97 points between the enhanced rose hips powder at 3 capsules and the original rose hips powder at 6 capsules.

“The results need to be confirmed in a phase 3 randomized controlled trial,” Christensen said.

Reference:

Christensen R. Paper #32. Presented at: Osteoarthritis Research Society International World Congress; April 18-21, 2013; Philadelphia.


Disclosure:
Orthopedics Today was unable to confirm disclosures at press time.